DAFTAR PUSTAKA

1. Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S,et al. (2008) Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib +chemotherapy—Cancer and Leukemia Group B Trial 30203. J Clin Oncol 26:848–55. pmid:1828165

2. Gitlitz BJ, Bernstein E, Santos ES, Otterson GA, Milne G, Syto M, et al.(2014) A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Thorac Oncol 9:577–82. pmid:24736085

3. Lilenbaum R, Socinski MA, Altorki NK, Hart LL, Keresztes RS, Hariharan S,etal.(2006).Randomized phase II trial of docetaxel/irinotecan and gemcitabine/ irinotecan with or without celecoxib in the second-line treatment of non- small-cell lung cancer. J Clin Oncol 24: 4825–32 pmid:17050867

4. Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, et al.(2011) Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4study. J Clin Oncol 29:4320–6. pmid:21990410

5. Reckamp KL, Koczywas M, Cristea MC, Dowell JE, Wang HJ, Gardner BK,et al.(2015)Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. Cancer 121:3298–306 pmid:26033830

6. Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, et al.(2015) Randomized, double-blind, placebo-controlled, multicenter phase ii study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-celllung cancer. J Clin Oncol. 33:189–94 pmid:25452446

7. Edelman MJ, Wang X, Hodgson L, et al. Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance) J Clin Oncol. 2017;35:2184–2192

8. Sandler AB, Dubinett SM.(2004) COX-2 inhibition and lung cancer. Semin Oncol 31:45–52.

9. Jiang H, Wang J, Zhao W.(2013) Cox-2 in non-small cell lung cancer: a meta-analysis.Clin Chim Acta 419:26–32. pmi

10. Verena J.(2013) Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett 332:313–24 pmid:21345578d:23384501

11. De Ruysscher D, Bussink J, Rodrigus P, Kessels A, Dirx M, Houben R, et al. (2007)Concurrent celecoxib versus placebo in patients with stageII-III non-small cell lung cancer: a randomised phase II trial. Radiother Oncol. 84:23–5. pmid:17532073

12. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Johnson DH, et al.(2009) A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res. 15:2158–65. pmid:19276291
13. Hida T, Kozaki K, Ito H, Tatematsu Y, Suzuki T, Suzuki T,et al.(2002) Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res 8: 2443–7 pmid:12114451
14. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, et al. (2003).Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.J Clin Oncol21:2645–50. pmid:12860939